Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - Pujade-Lauraine, E; Ledermann, J A; Selle, F; SOLO2/ENGOT-Ov21 investigators (Lancet Oncol, 2017)